Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.94 Insider Own19.92% Shs Outstand68.71M Perf Week-12.21%
Market Cap642.44M Forward P/E- EPS next Y-1.73 Insider Trans-0.23% Shs Float56.58M Perf Month11.31%
Income-111.30M PEG- EPS next Q-0.44 Inst Own57.80% Short Float29.94% Perf Quarter17.61%
Sales0.20M P/S3212.19 EPS this Y-15.70% Inst Trans0.19% Short Ratio12.85 Perf Half Y-20.09%
Book/sh1.22 P/B7.66 EPS next Y6.60% ROA-116.80% Target Price27.58 Perf Year117.44%
Cash/sh1.34 P/C7.00 EPS next 5Y- ROE-151.20% 52W Range4.10 - 15.35 Perf YTD14.02%
Dividend- P/FCF- EPS past 5Y40.90% ROI- 52W High-39.09% Beta1.35
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low128.05% ATR0.54
Employees69 Current Ratio4.90 Sales Q/Q0.00% Oper. Margin- RSI (14)55.31 Volatility5.82% 6.14%
OptionableYes Debt/Eq0.00 EPS Q/Q4.00% Profit Margin- Rel Volume0.55 Prev Close9.38
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 BMO Payout- Avg Volume1.32M Price9.35
Recom1.50 SMA204.44% SMA5010.96% SMA200-9.83% Volume726,212 Change-0.27%
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Mar-07-14Reiterated MLV & Co Buy $9 → $11
Nov-25-13Reiterated Ladenburg Thalmann Buy $8 → $12
Nov-06-13Initiated MLV & Co Buy $9
Jan-11-18 05:02PM  Why TG Therapeutics Rallied 15.7% Today Motley Fool +15.76%
Jan-08-18 07:30AM  TG Therapeutics, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:30AM  TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies GlobeNewswire
Jan-03-18 11:02AM  January Top Growth Stocks Simply Wall St. +5.71%
Dec-20-17 07:35AM  Market Trends Toward New Normal in TG Therapeutics, Boingo Wireless, Dave & Buster's Entertainment, Flagstar, Superior Industries International, and Benchmark Electronics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:22AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : December 20, 2017 Capital Cube
Dec-11-17 02:12PM  ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017 Capital Cube
10:38AM  TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer? Simply Wall St.
07:00AM  TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-17 08:06AM  TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Nov-30-17 02:28PM  ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:42AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 07:30AM  TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma GlobeNewswire
Nov-22-17 08:20AM  Todays Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics ACCESSWIRE
Nov-14-17 12:29PM  Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 08:03AM  TG Therapeutics reports 3Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 07:30AM  TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update GlobeNewswire -5.42%
Nov-01-17 09:30AM  TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-31-17 07:30AM  TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis GlobeNewswire
Oct-27-17 07:30AM  TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-26-17 07:30AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-17-17 08:10AM  Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE -9.16%
Oct-16-17 02:20PM  Why TG Therapeutics Is Tumbling 15% Today Motley Fool -15.68%
07:30AM  TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
07:30AM  TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial GlobeNewswire
07:30AM  TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Oct-12-17 08:24AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017 Capital Cube
Oct-05-17 07:30AM  TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development GlobeNewswire
Sep-29-17 08:47AM  Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX) Simply Wall St.
07:30AM  TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS) GlobeNewswire
Sep-28-17 10:30AM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : September 28, 2017 Capital Cube
Sep-27-17 08:17AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017 Capital Cube
Sep-21-17 07:30AM  TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Sep-15-17 07:30AM  TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment GlobeNewswire
Sep-13-17 11:01AM  Should You Buy TG Therapeutics Inc (TGTX) Now? Simply Wall St.
Sep-05-17 07:30AM  TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Sep-01-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Aug-31-17 09:31PM  ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-24-17 10:13AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 08:28AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017 Capital Cube
Aug-13-17 02:31AM  Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 07:30AM  TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial GlobeNewswire
Aug-09-17 01:01PM  TG Therapeutics reports 2Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
05:50AM  Investor Network: TG Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 05:04PM  What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool
07:30AM  TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update GlobeNewswire
Aug-03-17 11:37PM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : August 4, 2017 Capital Cube -5.88%
Aug-02-17 09:13AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017 Capital Cube
Aug-01-17 07:30AM  TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) GlobeNewswire
Jul-25-17 01:35PM  ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017 Capital Cube -5.81%
Jul-21-17 08:37AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017 Capital Cube
Jul-14-17 05:08PM  ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube
Jun-28-17 09:02AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube
Jun-26-17 07:30AM  TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire
07:00AM  TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire
Jun-21-17 06:48PM  Cramer's lightning round: This defeated stock is like flypaper CNBC
Jun-16-17 05:45AM  TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-15-17 04:21PM  New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool
03:27PM  ETFs with exposure to TG Therapeutics, Inc. : June 15, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire
04:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-14-17 12:00PM  TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma GlobeNewswire +5.16%
Jun-13-17 09:29AM  Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool
08:51AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 13, 2017 Capital Cube
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress GlobeNewswire
Jun-08-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire +5.69%
Jun-06-17 08:49AM  Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock? Zacks
07:30AM  TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
Jun-05-17 02:50PM  ETFs with exposure to TG Therapeutics, Inc. : June 5, 2017 Capital Cube -6.14%
10:56AM  U.S. stocks look for direction in shadow of U.K. terror attacks MarketWatch
09:43AM  Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal
09:37AM  UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results MarketWatch
09:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire
Jun-03-17 06:00PM  TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
Jun-02-17 05:37PM  Why TG Therapeutics Inc Jumped Higher Today Motley Fool +17.37%
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
May-26-17 12:46PM  5 Stocks Setting Up for Big Breakouts TheStreet.com
May-23-17 12:46PM  TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL TheStreet.com
07:30AM  TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial GlobeNewswire
May-22-17 08:17AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22, 2017 Capital Cube
May-19-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire
May-18-17 06:05AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire
May-17-17 05:05PM  TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
May-15-17 04:44PM  ETFs with exposure to TG Therapeutics, Inc. : May 15, 2017 Capital Cube
May-12-17 10:55AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube +6.33%
May-11-17 07:41PM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : May 11, 2017 Capital Cube
May-10-17 08:16AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 10, 2017 Capital Cube
May-05-17 08:22AM  3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool
07:42AM  TG Therapeutics reports 1Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 04:30PM  TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update GlobeNewswire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool
Apr-28-17 08:30AM  TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting GlobeNewswire -7.53%
Apr-26-17 03:38PM  ETFs with exposure to TG Therapeutics, Inc. : April 26, 2017 Capital Cube
03:23PM  Harry Boxers two infrastructure stocks to watch MarketWatch
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics Accesswire
Apr-25-17 06:59PM  Why TG Therapeutics Inc. Jumped Higher Today Motley Fool +15.38%
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Power Sean ACFO, Secretary and TreasurerJan 02Sale8.5032,006272,051485,458Jan 03 05:25 PM
Power Sean ACFO, Secretary and TreasurerJun 19Sale11.0430,000331,200447,464Jun 19 06:05 PM
Power Sean ACFO, Secretary and TreasurerJun 16Sale11.1429,976333,933477,464Jun 19 06:05 PM
KENNEDY WILLIAM JAMESDirectorApr 11Sale10.278,54887,78870,401Apr 12 05:44 PM
Charney Laurence NDirectorApr 04Sale11.177,00078,19088,949Apr 04 05:57 PM